NCT01940991View on ClinicalTrials.gov

Efficacy and Safety of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines

PHASE2CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Skin Aging
Interventions
DRUG

Placebo

Placebo, Dose B; dose applied to the lateral canthal lines

DRUG

Botulinum Toxin Type A

Botulinum Toxin Type A, Dose A, dose applied to the lateral canthal lines

Trial Locations (1)

33146

Dermatology Research Institute, Coral Gables

All Listed Sponsors
lead

Revance Therapeutics, Inc.

INDUSTRY

NCT01940991 - Efficacy and Safety of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines | Biotech Hunter | Biotech Hunter